Andrzej Jakubowiak

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi request reprint Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview
    Andrzej J Jakubowiak
    Section of Hematology Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637 6613, United States Electronic address
    Cancer Treat Rev 40:781-90. 2014
  2. pmc Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
    A J Jakubowiak
    Section of Hematology Oncology, University of Chicago Medical Center, Chicago, IL, USA
    Leukemia 27:2351-6. 2013
  3. ncbi request reprint A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
    Andrzej J Jakubowiak
    University of Chicago Medical Center, Chicago, IL 60637 6613, USA
    Blood 120:1801-9. 2012
  4. doi request reprint Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
    Andrzej J Jakubowiak
    University of Michigan Cancer Center, Ann Arbor, MI, USA
    Br J Haematol 158:472-80. 2012
  5. doi request reprint Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma
    Andrzej J Jakubowiak
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 30:1960-5. 2012
  6. doi request reprint Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives
    Andrzej Jakubowiak
    University of Chicago Medical Center, Chicago, IL 60637, USA
    Semin Hematol 49:S16-32. 2012

Detail Information

Publications6

  1. ncbi request reprint Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview
    Andrzej J Jakubowiak
    Section of Hematology Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637 6613, United States Electronic address
    Cancer Treat Rev 40:781-90. 2014
    ..Additional studies are underway to examine alternative dosing schedules (e.g., once-weekly dosing [CHAMPION-1])...
  2. pmc Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
    A J Jakubowiak
    Section of Hematology Oncology, University of Chicago Medical Center, Chicago, IL, USA
    Leukemia 27:2351-6. 2013
    ..4-NE); P=0.0003). Taken together, these findings demonstrate that single-agent carfilzomib is efficacious and has the potential to at least partially overcome the impact of high-risk cytogenetics in heavily pre-treated patients with MM...
  3. ncbi request reprint A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
    Andrzej J Jakubowiak
    University of Chicago Medical Center, Chicago, IL 60637 6613, USA
    Blood 120:1801-9. 2012
    ..CRd was well tolerated with exceptional response rates. This study is registered at http://www.clinicaltrials.gov as NCT01029054...
  4. doi request reprint Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
    Andrzej J Jakubowiak
    University of Michigan Cancer Center, Ann Arbor, MI, USA
    Br J Haematol 158:472-80. 2012
    ..Response was associated with phospho-Akt in pharmacodynamic studies. Perifosine-lenalidomide-dexamethasone was well tolerated and demonstrated encouraging clinical activity in relapsed and relapsed/refractory MM...
  5. doi request reprint Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma
    Andrzej J Jakubowiak
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 30:1960-5. 2012
    ..To evaluate the maximum-tolerated dose (MTD), safety, and efficacy of elotuzumab in combination with bortezomib in patients with relapsed or relapsed and refractory multiple myeloma (MM)...
  6. doi request reprint Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives
    Andrzej Jakubowiak
    University of Chicago Medical Center, Chicago, IL 60637, USA
    Semin Hematol 49:S16-32. 2012
    ....